AP HC Vacates Status Quo Order on Sun Pharma-Ranbaxy Merger - The New Indian Express

AP HC Vacates Status Quo Order on Sun Pharma-Ranbaxy Merger

Published: 24th May 2014 01:05 PM

Last Updated: 24th May 2014 01:08 PM

The Andhra Pradesh High Court on Saturday vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.

A petition in this regard was filed by two investors requesting the High Court to restrain the BSE and the NSE from giving any clearance to the scheme of amalgamation or merger between Sun Pharma and Ranbaxy.

The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.

They requested the court to direct market regulator SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street Developers.

The court had earlier issued interim orders to maintain status quo with regard to the merger.

Justice G Chandraiah today vacated the status quo. The SEBI had yesterday informed the court that an investigation is currently going on into the allegations of insider trading.

The bourses are yet to forward their opinion on the merger or amalgamation issue to the market regulator.

The Mumbai-based Sun Pharma had on April 6 announced that it would fully acquire Ranbaxy in an all-stockĀ  transaction with a total equity value of USD 3.2 billion, along with debt of USD 800 million, taking the overall deal value to USD 4 billion.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.


Read More



follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook